Line 1: |
Line 1: |
| {{review}} | | {{review}} |
| + | |
| + | ==Pharmacokinetics== |
| + | |
| + | Most drugs are transported in the aqueous phase of blood plasma. To |
| + | have an effect, a drug must reach cell membrane receptors or enter cells. |
| + | Absorption, distribution, biotransformation and elimination of drugs all |
| + | involve transfer across cell membranes, predominantly by passive diffusion |
| + | of un-ionised drugs down a concentration gradient. The ability of a drug to |
| + | cross biological membranes is determined primarily by its lipid solubility and |
| + | degree of ionisation. The degree of ionisation depends on both the acidic |
| + | dissociation constant (pKa) of the drug and the pH of the surrounding |
| + | fluid. Most drugs are weak acids or bases that are present in solution in |
| + | both the ionised and un-ionised forms, with only the latter able to cross |
| + | membranes. |
| + | |
| + | ==Pharmacokinetic parameters used for designing dosing regimes== |
| + | |
| + | * '''Bioavailability (F)''' gives an indication of the extent to which a drug enters the systemic circulation after absorption from its site of administration. Following intravenous (i.v.) administration the bioavailability is 100% |
| + | * '''Volume of distribution (Vd)''' is the apparent volume in the body in which a drug is dissolved. It is used to indicate how well a drug distributes to the tissues and is constant for any drug, only changing if there are physiological or pathological changes that alter drug distribution. Although a large Vd suggests excellent extravascular distribution, it does not guarantee adequate active drug concentrations at the site of action |
| + | * '''Clearance (CL)''' is the volume of plasma that is completely depleted of a drug to account for the rate of elimination. It is usually constant for a drug within the desired clinical concentrations but does not indicate how much drug is being removed |
| + | * '''Elimination half-life (t½)''' is the time required for the drug concentration to decrease by 50%. It is constant for most drugs and determines the timing of repeated doses. It takes around ten half-lives to eliminate 99.9% of a drug from the body |
| + | |
| + | ===Absorption=== |
| + | |
| + | Absorption is the rate and extent at which a drug leaves its site of |
| + | administration. It is influenced by many variables, including the dosage |
| + | form, e.g. solid forms must first dissolve. If the rate of absorption is very |
| + | slow, the drug may not reach active concentrations before it is eliminated |
| + | and, if very rapid unsafe plasma concentrations may be reached. |
| + | |
| + | ===Distribution=== |
| + | |
| + | Whether a drug is confined to the vascular space or distributes into the |
| + | intracellular and extracellular fluid (ECF) compartments depends on its |
| + | physicochemical properties, ''e.g.'' pKa, lipid solubility, molecular size and protein |
| + | binding. Weakly lipid soluble compounds, e.g. cephalosporins, aminoglycosides |
| + | and penicillins, generally penetrate poorly into cells: Vd approximates to the |
| + | ECF volume (adult horse 0.3 litres/kg) and changes in the ECF volume will |
| + | dramatically affect the plasma concentrations of these drugs. |
| + | |
| + | Highly lipophilic compounds, e.g. ivermectin and moxidectin, are |
| + | associated with large Vd, implying distribution into a volume greater than |
| + | the total body water (TBW, adult horse 0.6 litres/kg). These agents reach |
| + | high concentrations in tissues but relatively low concentrations in plasma |
| + | and are not usually affected significantly by changes in body water status. |
| + | Young foals tend to have a relatively high TBW and ECF volume, whereas |
| + | aged animals tend to have reduced TBW, primarily due to a reduction in |
| + | ECF volume. Dose rate adjustments may be required to achieve the desired |
| + | effective (therapeutic) and safe plasma concentrations in these animals. |
| + | |
| + | ===Metabolism=== |
| + | |
| + | Biotransformation, mainly in the hepatic smooth endoplasmic reticulum, |
| + | most commonly detoxifies and/or removes foreign chemicals from the |
| + | body but can also increase therapeutic activity (metabolic activation). The |
| + | enzymatic biotransformation of drugs into more polar, less lipid-soluble |
| + | (more water-soluble) metabolites promotes elimination. Conjugation of |
| + | drugs, e.g. to glucuronide, further increases their water solubility and hence |
| + | elimination. |
| + | |
| + | ===Elimination=== |
| + | |
| + | The kidney is the most important organ for elimination of drugs and |
| + | metabolites. |
| + | |
| + | Most organic acids, ''e.g.'' penicillin and glucuronide metabolites, are |
| + | actively transported into the proximal tubule by the same system that is |
| + | used for excretion of natural metabolites, e.g. uric acid. Organic bases are |
| + | transported by a separate system designed to excrete bases, ''e.g.'' histamine. |
| + | Although these systems are bi-directional, the main direction of transport |
| + | is into the renal tubules for excretion. The rate of passage into the renal |
| + | tubules is dependent on the pKa of the drug and its metabolites, and on |
| + | urine pH. Increasing urine pH can produce a dramatic increase in excretion |
| + | of acidic compounds, ''e.g.'' salicylate. |
| + | |
| + | Some drugs, ''e.g.'' those that remain unabsorbed following oral (per os) |
| + | administration and hepatic metabolites excreted into the bile by carrier |
| + | systems similar to those found in the kidney and not reabsorbed, are |
| + | eliminated via the gastrointestinal tract. Pulmonary excretion is important |
| + | for the elimination of anaesthetic gases. In lactating mares, excretion of |
| + | drugs in milk (usually weak bases) may be significant enough to affect |
| + | sucking foals. Other routes of excretion (skin, sweat, saliva) are generally |
| + | of minor importance. |
| + | |
| + | ===Enterohepatic recirculation=== |
| + | |
| + | Glucuronide conjugated metabolites undergo extensive enterohepatic |
| + | recirculation: a cycle of absorption from the gastrointestinal tract, |
| + | metabolism in the liver and excretion in bile, which prolongs elimination. |
| + | |
| + | ===Protein binding=== |
| + | |
| + | Many drugs are bound to plasma proteins (mainly albumin) in the |
| + | circulation. Bound drug is too large to pass through biological membranes, |
| + | so only free drug is available for delivery to the tissues. The degree of |
| + | protein binding is only of clinical significance for drugs that are more than |
| + | 90% protein-bound, ''e.g.'' non-steroidal anti-inflammatory drugs ([[NSAIDs]]), |
| + | sulphonamides, aminoglycoside antibiotics and warfarin. For these drugs, |
| + | conditions that significantly decrease plasma protein concentrations will |
| + | cause significant increases in the amount of free (active) drug. |
| + | '''Protein binding can be involved in drug interactions.''' Phenylbutazone |
| + | displaces warfarin from the protein-binding site. A reduction in the amount |
| + | of protein-bound warfarin from 99% to 98% effectively doubles the plasma |
| + | concentrations of free warfarin and can lead to bleeding problems. |
| + | |
| + | |
| + | <big> For more information see '''[[Basic Concepts of Pharmacology]]''' |
| + | |
| + | ==References== |
| + | |
| + | * Horspool, L. (2008) Clinical pharmacology In Svendsen, E.D., Duncan, J. and Hadrill, D. (2008) ''The Professional Handbook of the Donkey'', 4th edition, Whittet Books, Chapter 12 |
| + | |
| | | |
| {{toplink | | {{toplink |